STAT+: Pharmalittle: We're reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more

Intellia Therapeutics' gene editing treatment, lonvo-z, showed significant reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 trial, potentially becoming the second approved CRISPR-based medicine. This development matters as it represents a pioneering in vivo approach to gene therapy, directly editing patient DNA within the body, which could revolutionize treatment paradigms for rare genetic disorders.

Read the full article at STAT Pharma

---

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.